Evidence map›Paper›PMID 19726674›Full record

ArticleThe Journal of biological chemistry2009

Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.

Yasuhiro Nishiyama, Stephanie Planque, Yukie Mitsuda, Giovanni Nitti, Hiroaki Taguchi, Lei Jin, Jindrich Symersky, Stephane Boivin, Marcin Sienczyk, Maria Salas and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Neutralizing antibodies to HIV-1 induced by immunization.The Journal of experimental medicine · 2013
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yasuhiro NishiyamaDepartment of Pathology and Laboratory Medicine, Chemical Immunology Research Center, University of Texas-Houston Medical School, Houston, Texas 77030, USA.
Stephanie Planque
Yukie Mitsuda
Giovanni Nitti
Hiroaki Taguchi
Lei Jin
Jindrich Symersky
Stephane Boivin
Marcin Sienczyk
Maria Salas
Carl V Hanson
Sudhir Paul
The University of Texas Health Science Center at Houston · USCalifornia Department of Public Health · US

Funding

gp120 covalent analogs as candidate HIV vaccinesR01AI058865 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PAUL, SUDHIR · 2004 to 2008
$1.7M
beta-Amyloid Antibodies w/ Specific Proteolytic ActivityR01AG025304 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PAUL, SUDHIR · 2005 to 2008
$1.5M
RECOMBINANT SINGLE DOMAIN &HYBRID PEPTIDASE ANTIBODIESR01AI031268 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PAUL, SUDHIR · 1992 to 2002
$664k
Neutralizing antibodies raised by covalent immunizationR21AI062455 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI NISHIYAMA, YASUHIRO · 2006 to 2007
$439k
INNATE AND Ag-ADAPTED CHEMICALLY REACTIVE ANTIBODIESR21AI031268 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PAUL, SUDHIR · 2003 to 2003
$297k
Covalently reactive CD4 mimetics for inhibition of HIVR21AI058684 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI HANSON, CARL V · 2004 to 2005
$214k
A Rickettsial Symbiont Model for the Control of Tick-borne DiseasesR15AI082515 · NIAID · HUMBOLDT STATE UNIVERSITY · PI ZHONG, JIANMIN · 2009 to 2009
$210k
NIAID NIH HHS AI058684NIAID NIH HHS AI058865NIAID NIH HHS AI31268NIAID NIH HHS AI62455NIAID NIH HHS AI82515NIAID NIH HHS R01 AI031268NIAID NIH HHS R01 AI058865NIAID NIH HHS R15 AI082515NIAID NIH HHS R21 AI031268NIAID NIH HHS R21 AI058684NIAID NIH HHS R21 AI062455NIA NIH HHS AG025304NIA NIH HHS R01 AG025304
6 · The paper itself

Abstract

We describe murine monoclonal antibodies (mAbs) raised by immunization with an electrophilic gp120 analog (E-gp120) expressing the rare ability to neutralize genetically heterologous human immunodeficiency virus (HIV) strains. Unlike gp120, E-gp120 formed covalent oligomers. The reactivity of gp120 and E-gp120 with mAbs to reference neutralizing epitopes was markedly different, indicating their divergent structures. Epitope mapping with synthetic peptides and electrophilic peptide analogs indicated binary recognition of two distinct gp120 regions by anti-E-gp120 mAbs, the 421-433 and 288-306 peptide regions. Univalent Fab and single chain Fv fragments expressed the ability to recognize both peptides. X-ray crystallography of an anti-E-gp120 Fab fragment revealed two neighboring cavities, the typical antigen-binding cavity formed by the complementarity determining regions (CDRs) and another cavity dominated by antibody heavy chain variable (V(H)) domain framework (FR) residues. Substitution of the FR cavity V(H) Lys-19 residue by an Ala residue resulted in attenuated binding of the 421-433 region peptide probe. The CDRs and V(H) FR replacement/silent mutation ratios exceeded the ratio for a random mutation process, suggesting adaptive development of both putative binding sites. All mAbs studied were derived from V(H)1 family genes, suggesting biased recruitment of the V gene germ line repertoire by E-gp120. The conserved 421-433 region of gp120 is essential for HIV binding to host CD4 receptors. This region is recognized weakly by the FR of antibodies produced without exposure to HIV, but it usually fails to induce adaptive synthesis of neutralizing antibodies. We present models accounting for improved CD4-binding site recognition and broad HIV neutralizing activity of the mAbs, long sought goals in HIV vaccine development.

Indexed as

Epitope MappingAIDS VaccinesAmino Acid SubstitutionAnimalsCD4 AntigensCrystallography, X-RayEpitopesHIV AntibodiesHumansImmunoglobulin FragmentsMiceMolecular Sequence DataNeutralization TestsProtein ConformationAIDS VaccinesCD4 AntigensEpitopesHIV AntibodiesImmunoglobulin Fragments

Identifiers

PMID19726674
PMCPMC2781617
OpenAlexW2041467161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.